Matches in Wikidata for { <http://www.wikidata.org/entity/Q62110341> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q62110341 description "clinical trial" @default.
- Q62110341 description "ensayu clínicu" @default.
- Q62110341 description "klinisch onderzoek" @default.
- Q62110341 description "клінічне випробування" @default.
- Q62110341 description "临床试验" @default.
- Q62110341 name "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia" @default.
- Q62110341 type Item @default.
- Q62110341 label "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia" @default.
- Q62110341 prefLabel "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia" @default.
- Q62110341 P1050 Q62110341-2B979536-EA23-4A9D-9456-4E9C1E3F0850 @default.
- Q62110341 P1132 Q62110341-7C794B0E-F3CB-4B2A-B71E-3388DFE9CA26 @default.
- Q62110341 P1476 Q62110341-FCCEEA3F-7EBC-427D-9115-C513256038DE @default.
- Q62110341 P17 Q62110341-54F8B207-4C72-4BE6-8B19-58F3A6289840 @default.
- Q62110341 P3098 Q62110341-F9ACCF15-DAAB-4762-92CD-FCC287301C32 @default.
- Q62110341 P31 Q62110341-EE9D7D71-2369-45BF-A56B-188BD7D1F976 @default.
- Q62110341 P4844 Q62110341-174E6DCF-4873-437D-97BD-92A40293373A @default.
- Q62110341 P4844 Q62110341-9DDDE1E2-3551-4BC5-8063-2802576A6CFB @default.
- Q62110341 P4844 Q62110341-A5335F79-AA56-4640-9B8A-F90F4AD0777F @default.
- Q62110341 P580 Q62110341-8590235F-EF8A-48B0-B67F-B815ECD012F3 @default.
- Q62110341 P582 Q62110341-B8C8FDA5-AC09-4842-8691-B4B7EE6C8FAF @default.
- Q62110341 P6099 Q62110341-398B50B9-D7DF-4C37-A4AD-36EF4FFA14A0 @default.
- Q62110341 P6099 Q62110341-B9D00F2D-F5C6-424E-86BF-67212365F3D3 @default.
- Q62110341 P6153 Q62110341-4A143D56-CBEC-406F-A68B-6F7373D8DBF1 @default.
- Q62110341 P6153 Q62110341-7FD99077-732C-4798-BE64-8BBE83CAB3DA @default.
- Q62110341 P6153 Q62110341-856850F6-8723-493E-9530-BE63665AD1EB @default.
- Q62110341 P6153 Q62110341-87DD64E1-AE32-40AA-B463-8852A5FC010A @default.
- Q62110341 P6153 Q62110341-A9EDCE0A-63A7-463E-8945-8664E198C15D @default.
- Q62110341 P6153 Q62110341-C2822CC0-EC99-48DD-8F94-800BB5DF7660 @default.
- Q62110341 P6153 Q62110341-CF58E6E6-1CC8-4B3B-9E81-DC191F275A5A @default.
- Q62110341 P6153 Q62110341-D5E6128F-FEFF-48E2-A355-6BAE760C4C94 @default.
- Q62110341 P6153 Q62110341-EA631846-3461-40B7-84BE-DA1E441E259C @default.
- Q62110341 P8005 Q62110341-46ABBC83-E624-407E-874A-4CADD00E8D3B @default.
- Q62110341 P8363 Q62110341-ABFFA04C-711F-43E8-B5BC-238BA245C3E8 @default.
- Q62110341 P859 Q62110341-5909293C-F75F-4C89-8130-BDFA30855AF3 @default.
- Q62110341 P1050 Q29496 @default.
- Q62110341 P1132 "+410" @default.
- Q62110341 P1476 "Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years" @default.
- Q62110341 P17 Q30 @default.
- Q62110341 P3098 "NCT00002925" @default.
- Q62110341 P31 Q30612 @default.
- Q62110341 P4844 Q20801763 @default.
- Q62110341 P4844 Q411659 @default.
- Q62110341 P4844 Q418817 @default.
- Q62110341 P580 "1997-02-01T00:00:00Z" @default.
- Q62110341 P582 "2003-11-01T00:00:00Z" @default.
- Q62110341 P6099 Q42824440 @default.
- Q62110341 P6099 Q5452194 @default.
- Q62110341 P6153 Q1159198 @default.
- Q62110341 P6153 Q1808012 @default.
- Q62110341 P6153 Q1950740 @default.
- Q62110341 P6153 Q5225736 @default.
- Q62110341 P6153 Q6806451 @default.
- Q62110341 P6153 Q681025 @default.
- Q62110341 P6153 Q7370121 @default.
- Q62110341 P6153 Q777403 @default.
- Q62110341 P6153 Q7895888 @default.
- Q62110341 P8005 Q76651189 @default.
- Q62110341 P8363 Q78089383 @default.
- Q62110341 P859 Q664846 @default.